5-ht5A receptors as a therapeutic target

Pharmacology & Therapeutics
David R Thomas

Abstract

The 5-ht5A receptor is enigmatic among 5-HT receptors since, although the human receptor was cloned in 1994, until recently, very little has been learnt about the function of the receptor in native tissues. Findings from 5-ht5A receptor mRNA localisation and immunolabelling studies have revealed widespread expression in the CNS, and have provided pointers to the potential functional role(s) of the receptor. The expression of the 5-ht5A receptor in raphe nuclei and in higher brain areas, such as the cerebral cortex and hippocampus, suggests a potential autoreceptor function whilst localisation in the suprachiasmatic nucleus (SCN) suggests a role in circadian rhythm control. Additionally, 5-ht5A receptor knockout mouse phenotyping studies support a role in the control of exploratory behaviour. The lack of understanding of the role of the receptor has been, in part, due to the lack of available selective 5-ht5A receptor ligands. However, a selective 5-ht5A receptor antagonist, 3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride (SB-699551-A), has recently been identified which appears to be a useful tool with which to elucidate the physiological function of...Continue Reading

References

Jan 1, 1977·Psychoneuroendocrinology·L P MorinI Zucker
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·L MaroteauxR Hen
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M G ErlanderK Cannon
Dec 29, 1998·European Journal of Pharmacology·B J FranckenJ E Leysen
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Jan 22, 2000·Neuroscience Letters·Z Y WangG E Bisgard
May 12, 2000·British Journal of Pharmacology·D R ThomasG W Price
May 24, 2000·British Journal of Pharmacology·J J HaganD R Thomas
Feb 28, 2001·Journal of Biological Rhythms·R L Gannon
Apr 11, 2001·Brain Research. Molecular Brain Research·A M KinseyK R Oliver
Apr 21, 2001·Biological Psychiatry·K Pierce, E Courchesne
Apr 24, 2001·Molecular Psychiatry·N IwataD Goldman
Jun 27, 2002·Journal of Chemical Neuroanatomy·Frederik J GeurtsJean-Pierre Timmermans
Oct 24, 2002·Bioorganic & Medicinal Chemistry Letters·Ian T ForbesDavid R Thomas
Jan 22, 2003·Neuroscience Letters·R NicholsonK Lee
Jun 19, 2003·British Journal of Pharmacology·David R ThomasIan T Forbes
Feb 18, 2004·Current Drug Targets. CNS and Neurological Disorders·David R Thomas, Jim J Hagan
Jun 19, 2004·Journal of Psychiatric Research·C DubertretP Gorwood
Jun 24, 2004·European Journal of Pharmacology·David R ThomasPhilip D Hayes
Jul 30, 2004·The Journal of Comparative Neurology·Andrew G Ramage
Aug 17, 2004·European Archives of Psychiatry and Clinical Neuroscience·Jasminka StefuljBranimir Jernej

❮ Previous
Next ❯

Citations

Aug 19, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Carlos M Villalón, David Centurión
Jul 16, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Suneet MehrotraAntoinette MaassenVanDenBrink
Mar 16, 2013·Histochemistry and Cell Biology·Esther AsanKlaus-Peter Lesch
Dec 31, 2011·Human Genetics·Eric W KleeStephen C Ekker
Sep 29, 2011·Amino Acids·Anne SaulinRupert Lanzenberger
Jun 6, 2013·Behavioural Brain Research·Roberto GonzalezAlfredo Meneses
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark J Millan
Jan 29, 2008·Therapeutic Drug Monitoring·Offie P SoldinDaniel M O'Mara
Oct 12, 2013·Antioxidants & Redox Signaling·Mary A NdiayeNihal Ahmad
Oct 19, 2010·Psychopharmacology·Sylvia Navailles, Philippe De Deurwaerdère
Nov 19, 2015·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Mar 16, 2011·Neuroscience and Biobehavioral Reviews·Dave J Hayes, Andrew J Greenshaw
Sep 21, 2007·Neurochemistry International·Alice C DuttonNicholas M Barnes
Aug 12, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mayako YamazakiNobuya Matsuoka
Jan 1, 2014·Neuropharmacology·Caroline HanssonSuzanne L Dickson
Dec 25, 2013·Journal of Biomolecular Structure & Dynamics·Felipe MatsunagaRenyu Liu
Feb 14, 2014·Zygote : the Biology of Gametes and Early Embryos·Urszula StępińskaBożenna Olszańska
Jan 21, 2015·Pharmacology & Therapeutics·John D McCorvy, Bryan L Roth
May 20, 2014·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Jürgen GromballMartin Burkart
Oct 16, 2015·Journal of Psychopharmacology·Stephan KöhlerMazda Adli
Jun 30, 2007·Muscle & Nerve·Gualberto RuañoAlan H B Wu
Nov 22, 2013·Reviews in the Neurosciences·Alfredo Meneses
Aug 28, 2019·Journal of Psychopharmacology·Piotr PopikAgnieszka Nikiforuk
Oct 16, 2010·Physiological Research·M PytliakM Felšöci
May 15, 2008·Chemical Reviews·David E Nichols, Charles D Nichols
Jul 28, 2021·Pharmacology, Biochemistry, and Behavior·Bryan D AlvarezDionisio A Amodeo
Nov 14, 2007·Bioorganic & Medicinal Chemistry Letters·Jens-Uwe PetersLucinda Steward

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.